Back to today’s briefing

Story perspectives

Compass Pathways Shares Plunge 37% After Disappointing Trial Results

6/23/2025

24 3

Summary

Story summary

Shares of Compass Pathways Plc plummeted 37% as their psilocybin treatment for treatment-resistant depression fell short, achieving only a 3.6-point symptom reduction instead of the anticipated five. While the trial of 258 participants met its primary goal and showed no rise in suicidal thoughts, investor disappointment loomed large over this pivotal moment in psychedelic medicine.

1 of 1

Story summary

Shares of Compass Pathways Plc plummeted 37% as their psilocybin treatment for treatment-resistant depression fell short, achieving only a 3.6-point symptom reduction instead of the anticipated five. While the trial of 258 participants met its primary goal and showed no rise in suicidal thoughts, investor disappointment loomed large over this pivotal moment in psychedelic medicine.